Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study
Anna DeFazio(The University of Sydney), Jennifer Alsop(Manchester Academic Health Science Centre), Brooke L. Fridley(Children's Mercy Hospital), Zachary C. Fogarty(Mayo Clinic in Florida), Allan Jensen(Danish Cancer Society), Kunle Odunsi(University of Chicago), Marcus Q. Bernardini(University Health Network), Praful Ghatage(Breast Cancer Now), Helen Steed(University of Alberta), Claus Høgdall(Copenhagen University Hospital), Robert A. Vierkant(Mayo Clinic), David D.L. Bowtell(The University of Melbourne), Michael S. Anglesio(University of British Columbia), Gregg Nelson(Brigham and Women's Hospital), Jason Madore(QIMR Berghofer Medical Research Institute), Estrid Høgdall(University of Copenhagen), Quaid Morris(Kettering University), Wiam Bshara(National Institutes of Health), Martin Widschwendter(Universität Innsbruck), Matthias W. Beckmann(Universitätsklinikum Erlangen), Simon A. Gayther(The University of Texas Health Science Center at Houston), Arndt Hartmann(Universitätsklinikum Erlangen), Helen Mackay(Sunnybrook Health Science Centre), Aleksandra Gentry‐Maharaj(UCL Australia), Susan J. Ramus(Cancer Institute of New South Wales), Suha Deen(Nottingham University Hospitals NHS Trust), Shashikant Lele(Memorial Sloan Kettering Cancer Center), Patricia Shaw(Princess Margaret Cancer Centre), Barry P. Rosen(Florida International University), Sun Young Cho(University of Calgary), Kimberly R. Kalli(Mayo Clinic), Marie Mack(University of Cambridge), Maria P. Intermaggio(The University of Melbourne), Blaise Clarke(Princess Margaret Cancer Centre), Amit M. Oza(Ontario Institute for Cancer Research), Jennifer M. Koziak(Alberta Health Services), Carol A. Ewanowich(The University of Sydney), S. Liu(University of Calgary), Elizabeth Benjamin(LAC+USC Medical Center), Usha Menon(University of South Florida), Alexander Hein, Martin Köbel(University of Calgary), Paul D.P. Pharoah(Cedars-Sinai Medical Center), Gary L. Keeney(Mayo Clinic in Arizona), David L. Wachter, Falk C. Thiel(Comprehensive Cancer Center Erlangen), Lara Sucheston(Roswell Park Comprehensive Cancer Center), Mercedes Jimenez‐Liñan(University of Kansas), K E Driver(University of Cambridge)
Cited by 113
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Genomic Classification of Cutaneous Melanoma
|Cell|2015|3.3k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k